Click here for further information on ongoing studies with SIR-Spheres® Y-90 resin microspheres on www.clinicaltrials.gov

Liver Metastases

Title Setting Sponsor Study ID Treatment Arm(s) N Location
TAS-102 and radioembolisation with SIR-Spheres Y-90 resin microspheres for chemorefractory colorectal liver metastases Chemorefractory mCRC Investigator initiated study NCT02602327 TAS 102 + SIR-Spheres Y-90 resin microspheres 24 USA
SIRTAC
SIR-Spheres Y-90 resin microspheres vs. TACE treatment of uveal melanoma metastazised to liver
Uveal melanoma liver metastasis Investigator initiated study NCT02936388 SIR-Spheres Y-90 resin microspheres vs. TACE (cisplatin+embocept) 108 Germany
A feasibility study of sequential hepatic internal radiation and systemic ipilimumab and nivolumab in patients with uveal melanoma metastatic to liver Uveal melanoma liver metastasis Investigator initiated study NCT02913417 Sequential SIR-Spheres Y-90 resin microspheres > ipilimumab + nivolumab > nivolumab 18 USA

Primary Liver Cancer

Title Setting Sponsor Study ID Treatment Arm(s) N Location
Study of Y-90 radioembolisation with nivolumab in Asians with hepatocellular carcinoma Hepatocellular carcinoma Investigator initiated study NCT03033446 SIR-Spheres Y-90 resin microspheres > nivolumab 40 Singapore
NASIR-HCC
A study of the safety and antitumoral efficacy of nivolumab after SIRT for the treatment of patients with HCC
Hepatocellular carcinoma Investigator initiated study NCT03380130 SIR-Spheres Y-90 resin microspheres > nivolumab 40 Spain
SIRCCA
SIRT followed by CIS-GEM chemotherapy versus CIS-GEM chemotherapy alone as 1st line treatment of patients with unresectable intrahepatic cholangiocarcinoma
Intrahepatic cholangiocarcinoma Sirtex NCT02807181 SIR-Spheres Y-90 resin microspheres > cisplatin + gemcitabine vs. cisplatin + gemcitabine 180 Global
STOCS
This study aims to study the benefits of sequential administration of SIRT followed by standard chemotherapy for treatment of inoperable intrahepatic cholangiocarcinoma
Intrahepatic cholangiocarcinoma Investigator initiated study NCT02167711 SIR-Spheres Y-90 resin microspheres > gemcitabine + cisplatin 24 Hong Kong Singapore Thailand
MIRD
Current experience on yttrium-90 radioembolisation utilising resin microspheres with MIRD-model dosimetry
Intrahepatic cholangiocarcinoma and Hepatocellular carcinoma with portal vein invasion Investigator initiated study not registered SIR-Spheres Y-90 resin microspheres 25 USA

Liver Metastases and Primary Liver Cancer

Title Setting Sponsor Study ID Treatment Arm(s) N Location
AROMA
Abscopal effects after radioembolisation of metastatic colorectal cancer
mCRC, HCC, mBC Investigator initiated study not registered SIR-Spheres Y-90 resin microspheres 60 Germany

Registries

Title Setting Sponsor Study ID Treatment Arm(s) N Location
CIRT-FR
CIRSE registry for SIR-Spheres therapy in France
Primary and secondary liver tumors CIRSE NCT03256994 SIR-Spheres Y-90 resin microspheres 200 France
RESIN (USA)
Yttrium Y-90 resin microspheres data collection in unresectable liver cancer: the RESIN study
Primary and secondary liver tumors Investigator initiated study NCT02685631 SIR-Spheres Y-90 resin microspheres 3000 USA
ESSURE
European SIR-Spheres Surgical Registry
Primary and secondary liver tumors Investigator initiated study not registered SIR-Spheres Y-90 resin microspheres 250 Germany
BSIR SIRT Registry
British Society of Interventional Radiology
Primary and secondary liver tumors Investigator initiated study not registered SIR-Spheres Y-90 resin microspheres   UK
RESIN (Taiwan)
REgistry of Selective Internal radiation therapy in TaiwaN
Hepatocellular carcinoma Investigator initiated study NCT03292991 SIR-Spheres Y-90 resin microspheres 100 Taiwan, Singapore, Thailand
RESiN (ANZ)
Radiation-Emitting SIR-Spheres in Non-resectable Liver Tumor
Primary and secondary liver tumors Investigator initiated study not registered SIR-Spheres Y-90 resin microspheres >150 Australia and New Zealand

 

 



Now leaving sirtex.com

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.

Continue

×

You are now leaving your current sirtex.com region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.

Continue

×